Compare STTK & FRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | FRD |
|---|---|---|
| Founded | 2016 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.0M | 139.3M |
| IPO Year | 2020 | N/A |
| Metric | STTK | FRD |
|---|---|---|
| Price | $3.05 | $21.58 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 392.9K | 24.5K |
| Earning Date | 11-06-2025 | 02-06-2026 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | N/A | ★ 43.48 |
| EPS | N/A | ★ 1.63 |
| Revenue | $1,000,000.00 | ★ $510,450,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.13 |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $0.69 | $12.24 |
| 52 Week High | $3.38 | $23.50 |
| Indicator | STTK | FRD |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 58.13 |
| Support Level | $2.82 | $20.83 |
| Resistance Level | $3.30 | $21.79 |
| Average True Range (ATR) | 0.24 | 0.83 |
| MACD | -0.00 | 0.29 |
| Stochastic Oscillator | 74.76 | 84.62 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.